Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(3.66)
# 759
Out of 4,868 analysts
14
Total ratings
66.67%
Success rate
5.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Downgrades: Equal-Weight | $13 → $12 | $10.01 | +19.88% | 6 | May 28, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $9.43 | -15.16% | 2 | May 23, 2025 | |
| MRUS Merus | Maintains: Overweight | $91 → $89 | $52.59 | +69.23% | 1 | May 8, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $29 → $26 | $8.51 | +205.52% | 2 | May 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $37 → $33 | $8.36 | +294.97% | 2 | Feb 28, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Overweight | $34 | $27.93 | +21.73% | 1 | May 3, 2024 |
iTeos Therapeutics
May 28, 2025
Downgrades: Equal-Weight
Price Target: $13 → $12
Current: $10.01
Upside: +19.88%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $9.43
Upside: -15.16%
Merus
May 8, 2025
Maintains: Overweight
Price Target: $91 → $89
Current: $52.59
Upside: +69.23%
Arcus Biosciences
May 7, 2025
Maintains: Overweight
Price Target: $29 → $26
Current: $8.51
Upside: +205.52%
Xencor
Feb 28, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $8.36
Upside: +294.97%
Kiniksa Pharmaceuticals International,
May 3, 2024
Initiates: Overweight
Price Target: $34
Current: $27.93
Upside: +21.73%